[Systemic inflammation in spastic forms of cerebral palsy: pathogenetic role and modulation possibilities using Mexidol in motor rehabilitation of pediatric patients].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: To evaluate the ability of ethylmethylhydroxypyridine succinate (Mexidol) to modulate free radical oxidation rates and pro-inflammatory cytokine activity as a part of comprehensive medical rehabilitation for children diagnosed with spastic cerebral palsy. MATERIAL AND METHODS: The study cohort included children aged 6 to 8 years with spastic cerebral palsy (CP). Group 1 (n=24) received Mexidol in combination with robotic therapy incorporating biofeedback for 6 weeks. Group 2 (n=23) received only robotic therapy. Assessments were conducted on free radical oxidation indicators, serum levels of pro-inflammatory cytokines (tumor necrosis factor α [TNF-α] and interleukin-6 [IL-6]), and functional cognitive and motor indicators, utilizing data obtained from the integrated sensors of the exoskeleton platform. RESULTS: In children with spastic forms of cerebral palsy, two concurrent pathogenetic processes were observed: systemic inflammation, indicated by elevated levels of TNF-α and IL-6, and oxidative stress, marked by increased activity of antioxidant defense enzymes (peroxidase, catalase, and superoxide dismutase) alongside indicators of lipid peroxidation (malondialdehyde). The complex therapy demonstrated a statistically significant advantage in improving motor and cognitive indicators compared to robotic therapy only. Specifically, improvements in motor indicators ranged from 37.6% to 58.7%, while cognitive improvements ranged from 14.4% to 52.6%. These enhancements were found to significantly exceed those observed in the group receiving only robotic therapy (motor improvements of 24% to 39% and cognitive improvements of 5% to 22%; intergroup differences p<0.05). CONCLUSION: The combination therapy in children with spastic cerebral palsy effectively enhances both motor and cognitive functions while modulating antioxidant status and systemic inflammation. The integration of antioxidant pharmacotherapy into rehabilitation programs has been shown to increase the efficacy of training, thereby facilitating the development of a biomarker-driven approach to personalized treatment.